Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals, a global leader in specialty pharmaceuticals, is headquartered in the United Kingdom. Founded in 1867, the company has established a strong presence in key operational regions, including North America and Europe. With a focus on pain management, autoimmune disorders, and critical care, Mallinckrodt is renowned for its innovative therapies and unique formulations. The company’s core products, such as specialty generics and branded medications, are designed to address complex medical needs, setting them apart in a competitive market. Notable achievements include a robust portfolio of FDA-approved treatments and a commitment to advancing patient care through research and development. As a trusted name in the pharmaceutical industry, Mallinckrodt continues to make significant strides in improving health outcomes worldwide.
DitchCarbon Score
How does Mallinckrodt Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mallinckrodt Pharmaceuticals's score of 42 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Mallinckrodt Pharmaceuticals's reported carbon emissions
In 2023, Mallinckrodt Pharmaceuticals reported total carbon emissions of approximately 162,999,000 kg CO2e, comprising 13,880 kg CO2e from Scope 1 and 73,947,000 kg CO2e from Scope 2 emissions. Additionally, the company recorded Scope 3 emissions of about 674,530 kg CO2e, which included significant contributions from business travel and purchased goods and services. Mallinckrodt has set ambitious near-term reduction targets, aiming for a 23% reduction in total Scope 1 and 2 location-based emissions by 2030. This target is part of their first carbon reduction plan associated with Therakos operations in the UK, which aligns with UK government procurement policies. Furthermore, the company is committed to achieving Net Zero emissions for its UK operations by 2050, encompassing both Scope 1 and Scope 2 emissions. The company's emissions data reflects a proactive approach to climate commitments, with a focus on reducing its carbon footprint while adhering to industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000 |
| Scope 2 | - | - | 00,000,000 | 00,000 |
| Scope 3 | - | - | - | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mallinckrodt Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
